Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Wedbush Downgrades Global Blood Therapeutics to Neutral

Wedbush analyst Andreas Argyrides downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Neutral.
byBenzinga Newsdesk
August 8, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Wedbush analyst Andreas Argyrides downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts